FDA Advisory Committee recommends VIVUS obesity drug
The company has submitted new drug application (NDA) for Qnexa in October 2011. Qnexa is an investigational drug candidate being developed to address weight loss, type 2 Diabetes
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
The CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple MyEloma (ASPIRE) trial enrolled 780 patients at approximately 200 sites. The